

## **Promethazine downregulates Wnt/ $\beta$ -catenin signaling and increases biomechanical forces of injured Achilles tendon**

Takefumi Sakaguchi, MD<sup>1,2</sup>, Bisei Ohkawara, PhD<sup>1</sup>, Yasuzumi Kisimoto, MD, PhD<sup>1,2</sup>, Kentaro Miyamoto, MD, PhD<sup>1,2</sup>, Shinya Ishizuka, MD, PhD<sup>2</sup>, Hideki Hiraiwa, MD, PhD<sup>2</sup>, Naoki Ishiguro, MD, PhD<sup>2</sup>, Shiro Imagama, MD, PhD<sup>2</sup>, Kinji Ohno, MD, PhD<sup>1</sup>

<sup>1</sup>Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

<sup>2</sup>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

This study was performed in the Nagoya University, Graduate School of Medicine.

### **Correspondence to:**

Bisei Ohkawara, MD, PhD

Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

65 Tsurumai, Showa-ku, Nagoya, Aichi 466-8560, Japan

TEL: +81-52-744-2446; FAX: +81-52-744-2449

E-mail: biseiohkawara@med.nagoya-u.ac.jp

### **Competing Interests:**

The authors declare that no competing interests exist.

Running title : Promethazine for tendon injury

### **Author contributions**

T.S., B.O., and K.O. conceived the study and interpreted the results. T.S. and K.M. contributed to the rat experiments. T.S. and Y.K. contributed to the experiments using tendon-derived cells. S.I., and H.H. supervised the project. N.I. and K.O. provided financial support. T.S., B.O., and K.O. prepared the paper with assistance from the other authors.

### **Acknowledgements**

We would like to thank Ryusaku Esaki, Harumi Kodama, and Keiko Itano at Nagoya University Graduate School of Medicine for their technical assistance. The studies were supported by Grants-in-Aid from the Japan Society for the Promotion of Science (JP21K06392, and JP20H03561); the Ministry of Health, Labour and Welfare of Japan (20FC1036); the Japan Agency for Medical Research and Development (21gm1010002, JP21ek0109488, and 21bm0804005), the National Center of Neurology and Psychiatry (2-5), and the Hori Sciences and Arts Foundation.

1 **Promethazine downregulates Wnt/ $\beta$ -catenin signaling and**  
2 **increases biomechanical forces of injured Achilles tendon**

3  
4

5 **Competing Interests:**  
6 The authors declare that no competing interests exist.

7  
8 Running title: Promethazine for tendon injury

9  
10

11 **Abstract**

12 **Background:** The tendon rarely regains its initial functionality with sufficient biological and  
13 biomechanical properties after injury. One of the major challenges in tendon repair is that the cellular  
14 mechanisms underlying incomplete tendon repair remain largely elusive.

15 **Hypothesis/Purpose:** It has previously been reported that Wnt/ $\beta$ -catenin signaling suppresses the  
16 differentiation of tenocytes. We hypothesized that the inhibition of the Wnt/ $\beta$ -catenin signaling  
17 would promote the tendon repair and improve the biomechanical properties of the healing tendons.

18 **Study Design:** Controlled laboratory study.

19 **Methods:** The right Achilles tendon was injured by a dermal punch in rats. The left Achilles tendon  
20 was sham-operated as a control. The tendons were histologically analyzed on postoperative weeks  
21 0.5, 1, 2, 3, 4, and 8. Starting from the first postoperative day for 2 weeks, a Wnt/ $\beta$ -catenin inhibitor,  
22 IWR-1, was subcutaneously injected at the injured tendon, or a first-generation H1-antihistamine  
23 agent, promethazine (PH), was intramuscularly injected. Histological and biomechanical analyses  
24 were performed with the injured tendons. Tendon-derived cells (TDCs) were isolated to evaluate the  
25 effects of PH on the expression of the tendon marker genes by qRT-PCR.

26 **Results:** The amount of  $\beta$ -catenin protein in tendon cells was increased in the injured tendons from  
27 postoperative weeks 0.5 to 2. Histological analyses showed that the Bonar score representing the  
28 histological properties and the amount of  $\beta$ -catenin were lower in the IWR-1-treated injured tendons  
29 compared to those in the saline-treated injured tendons. IWR-1, however, compromised the  
30 biomechanical properties of the healing tendons. We first observed that PH increased the expressions  
31 of the tendon marker genes in TDCs. The amount of  $\beta$ -catenin in the PH-treated injured tendons was  
32 lower compared to that in the saline-treated injured tendons. In contrast to IWR-1, PH increased the  
33 peak force and stiffness of the healing tendons.

34 **Conclusion:** The inhibition of the Wnt/ $\beta$ -catenin signaling by IWR-1 improved histological repair of  
35 the Achilles tendons, but compromised the biomechanical properties. In contrast, PH reduced Wnt/ $\beta$ -  
36 catenin signaling and increased the biomechanical forces of the injured Achilles tendons.

37 **Clinical Relevance:** PH is a candidate repositioned drug that potentially increases the biomechanical  
38 forces of the healing tendons.

39

40 **What is known about this subject:** The tendon rarely regains its initial functionality with sufficient  
41 biological and biomechanical properties after injury. Wnt/ $\beta$ -catenin signaling suppresses the  
42 differentiation of cultured tenocytes.

43

44 **What this study adds to existing knowledge:** Injection of an inhibitor of the Wnt/ $\beta$ -catenin  
45 signaling, IWR-1, improved histological repair of the Achilles tendons, but compromised the  
46 biomechanical properties. In contrast, promethazine reduced Wnt/ $\beta$ -catenin signaling and increased  
47 the biomechanical forces of the injured Achilles tendons.

48

49 **Key Terms:** Promethazine; Achilles tendon; tendon healing; rat; drug repositioning; and  
50 biomechanics of the tendon

51

## 52 **Introduction**

53 Tendons are largely constituted of connective tissue that connects muscle and bone to transmit  
54 the biomechanical force for allowing for body movement.<sup>5</sup> Rupture of the Achilles tendon occurs  
55 with an incidence of 18.0 to 31.2 per 100,000 person-years, and its frequency is increasing.<sup>6,28</sup>  
56 Conservative and operative approaches are currently employed, but an injured tendon sometime  
57 heals with scar tissue and rarely achieves the functionality equivalent to that of the pre-injured state  
58 with appropriate biological and biomechanical properties.<sup>10</sup> Incomplete tendon healing may induce  
59 the recurrence of tendon rupture, which requires prolonged rehabilitation and compromises quality  
60 of life. The biomechanical properties of the tendon are dependent on the composition of the  
61 extracellular matrix proteins and fiber orientation.<sup>27</sup> In the last decades, many strategies to augment  
62 the biomechanical properties of injured tendons have been developed. Some growth factors, such as  
63 IGF-1<sup>16</sup>, BMPs<sup>26</sup>, and TGF- $\beta$ <sup>15</sup>, and their combinations<sup>20</sup> are promising therapeutic modalities in the  
64 healing of injured tendons. Biologically active adjuncts such as platelet-rich plasma are used in  
65 clinical practice.<sup>13</sup> Transplantation of embryonic stem cells, bone marrow-derived stromal cells, and  
66 endogenous tendon-derived cells (TDCs) enhances tendon repair in animal models.<sup>19</sup> Although  
67 cellular therapies are predicted to exert their effects via secreted proteins such as growth factors and  
68 extracellular matrix, the details need to be further dissected. A clinically applicable drug to augment  
69 the existing conservative and operative therapies is expected to be developed.

70 Tendon-related transcriptional factors, scleraxis (encoded by *Scx*) and mohawk (encoded by  
71 *Mkx*), are required for the differentiation of tenocytes, which secrete specific extracellular matrix  
72 including collagen types I and III. *Scx* is required for proper differentiation and is an important early  
73 marker in tendon development. Knockout of *Scx* results in the development of hypoplastic tendon  
74 tissues in the entire mouse body.<sup>23</sup> *Mkx* is required for tendon maturation by regulating type I  
75 collagen production in tendon cells. *Mkx*<sup>-/-</sup> mice show hypoplastic tendon tissues throughout the  
76 body.<sup>11</sup> An extracellular matrix protein, tenomodulin (encoded by *Tnmd*), is required for the  
77 maturation of collagen fibrils. *Tnmd* is highly expressed in mature tenocytes and is a late-phase  
78 marker of tendon development. The loss of *Tnmd* in tendons results in a low proliferative capacity of

79 tenocytes; hence, the collagen fiber bundles in tendons exhibit a non-uniform morphology.<sup>24</sup>

80         Similar to other growth factors, Wnt ligands and its downstream Wnt/ $\beta$ -catenin signaling play  
81 vital roles in the regulation of cellular functions and is involved in tissue healing and  
82 regeneration.<sup>25,2</sup> In the Wnt/ $\beta$ -catenin signaling, a Wnt ligand interacts with Frizzled (FZD) receptors  
83 on the cell surface. This induces the inhibition of the  $\beta$ -catenin destruction complex and then  
84 promotes the stabilization and nuclear translocation of  $\beta$ -catenin, which results in the activation of  
85 the target genes. It has previously been reported that the activation of Wnt/ $\beta$ -catenin signaling  
86 attenuates the differentiation of TDCs by suppressing gene expressions of *Scx*, *Mkx*, and *Tnmd*<sup>14</sup>, as  
87 well as by partially suppressing TGF- $\beta$  signaling. However, little is known about the spatiotemporal  
88 roles of Wnt/ $\beta$ -catenin signaling in injured tendons.

89         The purpose of this study was to identify the roles of Wnt/ $\beta$ -catenin signaling in injured  
90 tendons and to identify a potential drug that regulates the Wnt/ $\beta$ -catenin signaling to improve  
91 biomechanical properties of healing tendons. First, we detected a significant activation of Wnt/ $\beta$ -  
92 catenin signaling within 2 weeks after the tendon injury. When the activity of Wnt/ $\beta$ -catenin  
93 signaling was inhibited by IWR-1, abnormal production of mucopolysaccharides was reduced in the  
94 tendon tissue. In TDCs, promethazine (PH), a first-generation antihistamine agent that blocks the  
95 histamine H1 receptor, suppressed Wnt/ $\beta$ -catenin signaling and increased the expressions of *Mkx* and  
96 *Tnmd*. In a rat model of tendon injury, PH suppressed the activity of Wnt/ $\beta$ -catenin signaling and  
97 improved the mechanical forces of healing tendons.

98

## 99 **Materials and Methods**

100 A rat model of tendon injury

101         All animal studies were approved by the Animal Care and Use Committee of the [REDACTED]  
102 [REDACTED] and followed the guideline of the Institutional Animal Care and Use  
103 Committee. Six-week-old male Sprague-Dawley rats (weighting 170–220 g, Japan SLC, Inc.) were  
104 subjected to isolation of TDCs, as well as to histological and biomechanical studies. The rats for  
105 histological and mechanical studies were anesthetized with 2.5% sevoflurane. Under aseptic

106 conditions, the right Achilles tendon was injured with a dermal punch (Seiken Torepan, KAI) at the  
107 midpoint between the calcaneus and the gastrocnemius muscle. Thereafter, the skin was sutured with  
108 a 5-0 nylon thread. The left Achilles tendon was exposed, but the tendon remained uninjured (sham-  
109 operated tendon). On postoperative weeks 0.5 (postoperative day 3), 1, 2, 3, 4 and 8, the rats were  
110 euthanized with carbon dioxide (CO<sub>2</sub>), and the Achilles tendon complex (Achilles tendon with the  
111 calcaneus and the gastrocnemius muscle) was isolated and stained with hematoxylin-eosin (HE) and  
112 Alcian blue. Tendon repairs were graded according to the Bonar score<sup>3</sup> on the operated tendon  
113 tissues. The Bonar score is a sum of the following four parameters; appearance of tenocytes, grades  
114 0 (elongated spindle shape) to 3 (large cell with round nucleus and abundant cytoplasm); ground  
115 substance, grade 0 (no stainable ground substance) to 3 (abundant mucin with inconspicuous  
116 collagen staining); collagen, grade 0 (tightly cohesive arrangement of fibers) to 3 (marked separation  
117 of fibers with loss of architecture); and vascularity, grades 0 (inconspicuous blood vessels) to 3  
118 (more than two clusters of capillaries per tissue). A blinded observer evaluated the grades of tendon  
119 repair from 0 (healthy tendon) to 12 (severely injured tendon), and the average in each group of rats  
120 was calculated.

121

#### 122 Immunostaining for $\beta$ -catenin protein

123 For immunostaining, sections of the paraffin-embedded tendon were first deparaffinized and  
124 rehydrated. Serial sections were incubated with a rabbit antibody against  $\beta$ -catenin (BD Transduction  
125 Laboratories, 1:200 dilution) at 4°C overnight and then incubated with a secondary donkey antibody  
126 against rabbit IgG (H+L) conjugated with Alexa Fluor 488 (Thermo Fisher #A21206, 1: 1,000  
127 dilution) at room temperature for 1 h. The sections were mounted in Vectashield containing 2 ng/ml  
128 diamidino-2-phenylindole (DAPI, Vector Laboratories), as described previously.<sup>14</sup> The image was  
129 observed using a confocal laser scanning microscope system (TiE-A1R, Nikon). The total and  
130 nuclear signal intensities of  $\beta$ -catenin were automatically quantified in three tendons in each group  
131 using the MetaMorph software (Molecular Device). We analyzed two areas of the injured tendon,  
132 and one area of the sham-operated tendon. Each area was comprised of ~36,000  $\mu\text{m}^2$ . Nucleus was

133 stained with DAPI. Total cellular and total nuclear signal intensities of  $\beta$ -catenin were normalized by  
134 those of the sham-operated tendons on postoperative week 0.5 or those of vehicle-treated tendons.

135

136 Drug administration

137 IWR-1 (Tocris #3532) was first dissolved in dimethyl sulfoxide (DMSO) to make a 50 mM  
138 stock solution. IWR-1 was then diluted in saline at 5  $\mu$ M, and 100  $\mu$ l of 5  $\mu$ M IWR-1 or saline with  
139 DMSO was administered subcutaneously around the right Achilles tendon every day from the first  
140 postoperative day for 2 weeks. PH (20-30 mg, TCI P2029) was dissolved in saline, and 1 mg/kg/day  
141 of PH or saline was intramuscularly injected into the quadriceps muscle twice a day from the first  
142 postoperative day for 2 weeks.

143

144 Primary culture of tendon-derived cells (TDCs)

145 SD rats (6-week-old males, weighting 170–220 g) were euthanized with CO<sub>2</sub>, and TDCs were  
146 isolated from the Achilles tendon, as previously reported.<sup>14</sup> After resecting the paratenon and muscle,  
147 the Achilles tendon was cut into ~1-mm pieces and placed in a 10-cm culture plate filled with  
148 Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies) supplemented with 10% fetal  
149 bovine serum and 1% penicillin-streptomycin (10,000 U/ml, Gibco). After incubating the cells in a  
150 humidified chamber with 5% CO<sub>2</sub> at 37°C for 14 days, the cells were detached with trypsin-EDTA,  
151 and seeded in a new plate. After two passages, the cells were seeded in a six-well plate at a density  
152 of  $3 \times 10^5$  cells/well and cultured for 2 days. Then, the cells were supplemented with 0, 0.5, 1, 2, or 5  
153  $\mu$ M PH (Wako, 165-24142), 2  $\mu$ M ethopropazine (FCS, 10-1559), 2  $\mu$ M hydroxyzine (LKT,  
154 H97171), 2  $\mu$ M IWR-1, 2  $\mu$ M BIO (Sigma, #B1686), 50 ng/ml human recombinant Wnt3a protein  
155 (R&D Systems, #5036-WN), 2  $\mu$ M SD208 (Wako, 193–16331), and/or 1  $\mu$ M LDN-193189  
156 (Cayman, 11802) for 48 h.

157

158 Total RNA extraction and quantitative RT-PCR

159 Total RNA in TDCs was isolated using QuickGene RNA cultured cell kit (Kurabo) on



160 QuickGene-800 (Kurabo). The first strand cDNA was synthesized with ReverTra Ace (Toyobo). We  
161 quantified mRNA expressions for *Scx*, *Mkx*, and *Tnmd* as tenogenic genes, and for *Axin2* as an  
162 indicator of activated Wnt/ $\beta$ -catenin signaling using LightCycler 480 (Roche) and SYBR Green  
163 (Takara). The mRNA levels were normalized by *Gapdh*. Primer sequences are shown in  
164 Supplementary Table S1.

165

#### 166 Biomechanical tests

167 Biomechanical tests were performed as described elsewhere.<sup>1,4</sup> Briefly, at postoperative week  
168 2, rats were euthanized with CO<sub>2</sub>. Bilateral Achilles tendons with the calcaneal bone and the  
169 gastrocnemius/soleus muscles were harvested. The sagittal and transverse diameters of the mid part  
170 of the Achilles tendons were measured by an electronic digital caliper. The cross sectional areas were  
171 calculated assuming an elliptic cylindrical shape as described previously.<sup>9</sup> The gastrocnemius and  
172 soleus muscles were scraped off from the tendon, and tendon fibers were fixed in a metal clamp with  
173 sandpaper. The calcaneal bone was fixed in a metal clamp at 30° dorsiflexion. The mechanical  
174 testing machine (ZTA-500N/EMX-1000N IMADA) pulled the fixed tendon at a constant speed (0.1  
175 mm/s) until the tendon was ruptured. The data acquisition rate was set at every 0.03 sec. The peak  
176 force at failure (N) and stiffness (N/mm) were calculated by the testing machine. We quantified the  
177 stiffness from the linear part of the elastic phase in the force extension curve. The elastic modulus  
178 and peak stress were estimated by the cross-sectional areas.

179

#### 180 Statistical analysis


181 All data were presented as the mean  $\pm$  standard error of the mean (SEM). Statistical  
182 significance was evaluated by either Student's *t*-test, one-way ANOVA with Tukey-Kramer post-hoc  
183 test, or two-way repeated measures ANOVA with Tukey-Kramer post-hoc test. The Jonckheere -  
184 Terpstra trend test was used to evaluate the dose dependence. The threshold for significance was all  
185 set to be  $p < 0.05$ . The statistical analyses were performed with SPSS statistics 23 (IBM).

186

187 **Results**

188 Tendon injury activates Wnt/ $\beta$ -catenin signaling and worsens the biomechanical properties

189         It has previously been reported that Wnt/ $\beta$ -catenin signaling attenuates the differentiation of  
190 TDCs by suppressing gene expressions of *Scx*, *Mkx*, and *Tnmd*, partially through suppressing TGF- $\beta$   
191 signaling.<sup>14</sup> To examine the changes of activity of Wnt/ $\beta$ -catenin signaling over time in tendon cells  
192 following tendon injury, we analyzed the accumulation of  $\beta$ -catenin during the healing process of the  
193 injured tendons. The rat Achilles tendon was injured by a dermal punch on day 0, and its sagittal  
194 section was stained with HE or Alcian blue, and immunostained for  $\beta$ -catenin on postoperative  
195 weeks 0.5, 1, 2, 3, 4 and 8 (Fig. 1A, B). HE staining showed that collagen fibers at the injured sites  
196 were first replaced by small and round inflammatory cells on postoperative week 0.5. The  
197 inflammatory cells were gradually replaced by flattened and elongated tendon cells on postoperative  
198 weeks 1 to 4, and finally changed to scar tissue on postoperative week 8 (Fig. 1A). Alcian blue  
199 staining on postoperative weeks 1 and 2 showed an abnormal accumulation of mucopolysaccharides  
200 at the injured site, which probably represented chondroid tissue (Fig. 1A). In the tendon cells at the  
201 injured site, the accumulation of total cellular and total nuclear  $\beta$ -catenin protein peaked at  
202 postoperative week 1 and gradually decreased until postoperative week 8 (Fig. 1B-D). We then  
203 measured biomechanical properties, and found that peak force, stiffness, peak stress, and elastic  
204 modulus were lower in the injured Achilles tendons, although statistical significance was observed  
205 only in elastic modulus on postoperative weeks 2 (Fig. 1E). We also found that tendon injury  
206 increased the cross-sectional area of the tendon. Thus, tendon injury activated Wnt/ $\beta$ -catenin  
207 signaling in tendon cells at the injured site, and compromised biomechanical properties.



208

209 **Fig 1. Time course of tendon histology and  $\beta$ -catenin protein in injured rat Achilles tendon.**

210 **(A)** High- and low-power field images of hematoxylin-eosin (HE) staining, and low-power field

211 images of Alcian blue staining of sagittal sections of the injured tendon on postoperative weeks 0.5

212 to 8 and sham-operated tendons on postoperative week 0.5. Positions of high-power field images are

213 indicated by squares. Positions of the injured sites are indicated by a double-headed arrow. Scale bar

214 = 100  $\mu$ m (higher power field) or 500  $\mu$ m (lower power field). **(B)** Immunostaining for  $\beta$ -catenin

215 (green) with DAPI (blue). Scale bar = 10  $\mu$ m. **(C, D)** Mean and SEM ( $n = 3$  rats) of signal intensities

216 of total cellular and total nuclear  $\beta$ -catenin of the tendon cells. Each intensity is normalized by the

217 intensity of sham-operated tendon on postoperative week 0.5. \* $p < 0.05$  and \*\* $p < 0.01$  by two-way


218 repeated measures ANOVA followed by Tukey-Kramer post-hoc test. **(E)** Mean and SEM ( $n = 3$

219 rats) of peak force, stiffness, peak stress, elastic modulus, and cross sectional area of injured and  
220 sham-operated Achilles tendons on postoperative weeks 2.  $*p < 0.05$  and  $**p < 0.01$  by Student's *t*-  
221 test.

222

223 Suppression of Wnt/ $\beta$ -catenin signaling by IWR-1 reduces the formation of scar tissue, but  
224 compromises the biomechanical properties of the injured tendon

225 To examine the role of Wnt/ $\beta$ -catenin signaling in the early phase of the healing process for  
226 the tendon tissue, IWR-1 was injected to the subcutaneous space around the tendon once a day from  
227 the first postoperative day for 2 weeks. IWR-1 is a specific inhibitor for Wnt/ $\beta$ -catenin signaling via  
228 the stabilization of  $\beta$ -catenin destruction complex. Compared to vehicle-injected tendons, abnormal  
229 accumulation of mucopolysaccharides was decreased in the middle part of the IWR-1-treated  
230 tendon, while no remarkable difference in the cell shapes of tendon cells was observed in both  
231 vehicle- and IWR-1-treated tendons by HE staining on postoperative weeks 2 (Fig. 2A). The  
232 histological Bonar scores for the IWR-1-treated tendons were low (Fig. 2B). We assessed  
233 immunostaining for  $\beta$ -catenin of the injured tendon, and showed that the signal intensities of total  
234 cellular and total nuclear  $\beta$ -catenin were both significantly lower in the IWR-1-treated group (Fig.  
235 2C, D). We then measured the effects of IWR-1 on biomechanical properties of the injured tendons,  
236 and found that IWR-1 treatment tended to compromise biomechanical properties including peak  
237 force, stiffness, peak stress, and elastic modulus. We also examined the sham-operated tendon, and  
238 found that IWR-1 injected on the injured side abnormally lowered the Bonar score and impaired  
239 biomechanical properties (Supplementary Fig. S1A, B). These results suggest that IWR-1 suppressed  
240 Wnt/ $\beta$ -catenin signaling, reduced accumulation of  $\beta$ -catenin in the nucleus and the cell, and  
241 compromised biomechanical features of the healing tendon.



242

243 **Fig 2. IWR-1 suppressed β-catenin signal, and compromised biomechanical properties in the**  
 244 **injured rat Achilles tendon.**

245 **(A)** Hematoxylin-eosin (HE) and Alcian blue staining of sagittal sections of injured tendons on  
 246 postoperative weeks 2 with/without subcutaneous IWR-1 administration. Scale bar = 500 μm. **(B)**  
 247 The average of the Bonar scores of the vehicle- and IWR-1-treated groups is indicated by mean and  
 248 SEM ( $n = 3$  rats each).  $*p < 0.05$  by Student's test. **(C)** Immunostaining of vehicle- and IWR-1-  
 249 treated groups for β-catenin (green) with DAPI (blue). Scale bar = 10 μm. **(D)** Mean and SEM ( $n = 3$   
 250 rats) of signal intensities of total cellular and total nuclear β-catenin of the tendon cells. Signal  
 251 intensities of β-catenin in IWR-1-treated tendon are normalized by those in vehicle-treated tendons.  
 252  $*p < 0.05$  and  $**p < 0.01$  by Student's test. **(E)** Mean and SEM ( $n = 3$  rats) of peak force, stiffness,  
 253 peak stress, elastic modulus, and cross sectional area of injured Achilles tendons of vehicle- and  
 254 IWR-1-treated groups. No statistical significance by Student's  $t$ -test.


255

256 Promethazine (PH) suppresses Wnt/ $\beta$ -catenin signaling and increases *Mkx* and *Tnmd* expressions in

257 TDCs

258 It has previously been reported that 5-10  $\mu$ M of IWR-1 increased the gene  
259 expressions of *Scx*, *Mkx*, and *Tnmd*  $\sim$ 1.2- to  $\sim$ 1.8-folds in TDCs.<sup>14</sup> However, Wnt/ $\beta$ -catenin signaling  
260 suppresses apoptosis of cultured TDCs caused by anti-inflammatory drugs<sup>30</sup>, suggesting that  
261 suppression of a basal level of Wnt/ $\beta$ -catenin signaling may have an adverse effect on cell survival  
262 in the tendon. Indeed, the IWR-1 injection attenuated the biomechanical properties of both injured  
263 and sham-operated tendons (Fig. 2E and Supplementary Fig. S1B). We accordingly looked for a  
264 clinically approved drug that weakly suppresses Wnt/ $\beta$ -catenin signaling. It has previously been  
265 reported that antihistamine agents suppressed Wnt/ $\beta$ -catenin signaling in HCS-2/8 human  
266 chondrosarcoma cells.<sup>22</sup> We thus examined the effects of promethazine (PH), phenothiazine,  
267 ethopropazine, and hydroxyzine. PH is a first-generation antihistamine agent that is derived from  
268 phenothiazine. Ethopropazine is another derivative of phenothiazine. Hydroxyzine is another first-  
269 generation antihistamine agent that was not derived from phenothiazine.

270 We isolated TDCs from the rat Achilles tendon<sup>14</sup>, and examined the expressions of tendon-  
271 specific genes of *Scx*, *Mkx*, and *Tnmd*, as well as Wnt/ $\beta$ -catenin signaling by examining the  
272 expression of its target gene, *Axin2*. We found that only PH downregulated the expression of *Axin2*,  
273 and upregulated the expressions of *Mkx* and *Tnmd* in TDCs in a dose-dependence manner (Fig. 3A,  
274 B). PH, however, had no effect on the expression of *Scx*. The other three compounds had no effects  
275 on the expression of these genes. Wnt3A reduced the expressions of *Mkx* and *Tnmd*, and PH rescued  
276 the reduction (Fig. 3C). Additionally, PH-mediated increase of *Mkx* and *Tnmd* expressions was  
277 attenuated by inhibitors of the TGF- $\beta$  superfamily receptors (SD208 for ALK5 and LDN-193189 for  
278 ALK2/3). These results suggest that PH increased the expressions of *Mkx* and *Tnmd* in TDCs, likely  
279 by down-regulating Wnt/ $\beta$ -catenin signaling and up-regulating TGF- $\beta$  signaling.



280


281 **Fig 3. Promethazine (PH) suppressed Wnt/ $\beta$ -catenin signaling and increased mRNA**  
 282 **expressions of *Mlx* and *Tnmd* in rat tendon-derived cell (TDCs).**

283 Relative expressions of *Axin2*, *Scx*, *Mlx*, and *Tnmd* in TDCs treated with 2  $\mu\text{M}$  of PH,  
 284 phenothiazine, ethopropazine, hydroxyzine (A), 0 to 5  $\mu\text{M}$  of PH (B), 2  $\mu\text{M}$  of PH and/or 50 ng/ml  
 285 of Wnt3A (C), 2  $\mu\text{M}$  of PH with 2  $\mu\text{M}$  of SD208 or 1  $\mu\text{M}$  of LDN193189 (D) for 48 h. Each mRNA  
 286 expression is normalized by *Gapdh* mRNA, and then normalized with those for untreated cells.  
 287 Mean and SEM are indicated ( $n = 3$  wells each). After one-way ANOVA, statistically similar items  
 288 were grouped together according to the Tukey-Kramer post-hoc test ( $p < 0.05$ ), and each group was  
 289 labeled by an identical single lowercase letter (A, C, D). *P*-values by the Jonckheere-Terpstra trend  
 290 test to evaluate dose dependency are indicated at the top of the graph (B).

291 PH suppresses Wnt/ $\beta$ -catenin signaling and improves biomechanical properties in a rat model of  
292 tendon injury

293 PH is approved to be administered subcutaneously, intramuscularly, and intraorally.<sup>8</sup> To  
294 evaluate the effect of PH on injured tendons, PH was administered intramuscularly twice a day from  
295 the first postoperative day for 2 weeks in a rat model of tendon injury. PH treatment demonstrated no  
296 remarkable changes in HE and Alcian blue stainings as well as in the Bonar score (Fig. 4A, B). We,  
297 however, observed that immunofluorescent signals for total cellular and total nuclear  $\beta$ -catenin in  
298 tendon cells were significantly reduced by PH treatment (Fig. 4C, D). Additionally, the injured  
299 tendons treated with PH had higher biomechanical properties in peak force and stiffness, and higher  
300 cross section areas (Fig. 4E). In contrast to the adverse effects of IWR-1 on the sham-operated  
301 tendon (Supplementary Fig. 1A, B), PH had no effect on the biomechanical properties of sham-  
302 operated tendons (Supplementary Fig. S1C, D). These results suggest that intramuscular injection of  
303 PH suppressed Wnt/ $\beta$ -catenin signaling and improved the biomechanical features of the healing  
304 tendon in a rat model.





**Fig 4. Suppression of  $\beta$ -catenin signal by promethazine (PH) improved biomechanical properties in the injured rat Achilles tendon.**

(A) Hematoxylin-eosin (HE) and Alcian blue staining of sagittal sections of injured tendons on postoperative day 14 with/without PH administration. Scale bar = 500  $\mu$ m. (B) The average of the Bonar scores of vehicle- and PH-treated groups are indicated by mean and SEM ( $n = 3$  rats each). No statistical difference by Student's  $t$ -test. (C) Immunostaining of vehicle- and PH-treated groups for  $\beta$ -catenin (green) with DAPI (blue). Scale bar = 10  $\mu$ m. (D) Mean and SEM ( $n = 3$  rats each) of signal intensities of total cellular and total nuclear  $\beta$ -catenin of the tendon cells. Each intensity is normalized by the intensity of vehicle. \* $p < 0.05$  and \*\* $p < 0.01$  by Student's  $t$ -test. (E) Mean and SEM ( $n = 3$  rats each) of peak force, stiffness, peak stress, elastic modulus, and cross sectional area of injured Achilles tendons of vehicle- and PH-treated groups. \* $p < 0.05$  by Student's  $t$ -test.

318 **Discussion**

319 Wnt/ $\beta$ -catenin signaling plays a vital role in tissue healing and regeneration, as well as in  
320 tissue development.<sup>21,17</sup> However, little is known about the roles of Wnt/ $\beta$ -catenin signaling in  
321 tendon repair. In this study, we found that Wnt/ $\beta$ -catenin signaling was activated in tendon cells in 2  
322 weeks after tendon injury (Fig. 1B), when the tissue had abnormal accumulation of  
323 mucopolysaccharides (Fig. 1A). We also found that the accumulation of mucopolysaccharides (Fig.  
324 2A) and high Bonar scores (Fig. 2B) were ameliorated by local administration of IWR-1, an  
325 inhibitor for Wnt/ $\beta$ -catenin signaling on 2 weeks after tendon injury. In accordance with our  
326 observations, other authors reported that prolonged upregulation of Wnt signaling led to delayed  
327 tendon-to-bone healing.<sup>29</sup> Taken together, Wnt/ $\beta$ -catenin signaling is activated for 2 weeks after  
328 tendon injury and is likely to increase extracellular matrix proteins including mucopolysaccharides at  
329 the injured site.

330 As inhibition of Wnt/ $\beta$ -catenin signaling is a potential therapeutic target for injured tendons,  
331 we injected IWR-1 subcutaneously at the injured Achilles tendon to deliver a high concentration of  
332 IWR-1 to the tendon but minimally to the neighboring tissues. Although IWR-1 injection  
333 ameliorated abnormal accumulation of mucopolysaccharides and lowered the Bonar score, IWR-1  
334 injection rather compromised the biomechanical properties of both injured and sham-operated  
335 tendons (Fig. 2E). As IWR-1 is a potent and extensive inhibitor of Wnt/ $\beta$ -catenin signaling and has  
336 not been developed for therapeutic purposes, we looked for a drug-repositioned compound with  
337 similar Wnt/ $\beta$ -catenin signaling-inhibiting effects.

338 Here we found that PH, a first-generation antihistamine agent, suppressed Wnt/ $\beta$ -catenin  
339 signaling in TDCs. Similar effects, however, were not observed in its parental compound,  
340 phenothiazine, or in the other antihistamine agents, ethopropazine or hydroxyzine (Fig. 3A, B). PH  
341 significantly upregulated the expressions of both *Mkx* and *Tnmd* in TDCs, probably through down-  
342 regulation of Wnt/ $\beta$ -catenin signaling and up-regulation of the TGF- $\beta$  signaling (Fig.3C, D). In  
343 addition to the antihistamine effect of PH, facilitation of tendon healing was reported in chicken in  
344 1961,<sup>18</sup> and prevention of peritoneal adhesions was reported in rat in 1975.<sup>7</sup> We also reported that

345 PH suppressed the abnormal osteogenic differentiation of platelet-derived growth factor receptor  $\alpha$   
346 (PDGFR $\alpha$ )-positive mesenchymal progenitors in skeletal muscle without overt adverse effects in an  
347 animal model.<sup>12</sup> We showed in a rat model of tendon injury that intramuscular injection of PH  
348 significantly reduced Wnt/ $\beta$ -catenin signaling (Fig. 4C, D) and improved the biomechanical features  
349 of the healing Achilles tendon in 2 weeks after the injury (Fig. 4E).

350 In conclusion, we identified that PH suppressed Wnt/ $\beta$ -catenin signaling in tendon cells.  
351 Although additional non-clinical and clinical studies are required to optimize the dosage and the  
352 administration protocol, we propose that a pre-approved drug, PH, is a promising compound that can  
353 be potentially applied for the treatment of tendon injury in humans.

354

#### 355 **Author contributions**

356 T.S., B.O., and K.O. conceived the study and interpreted the results. T.S. and K.M. contributed to the  
357 rat experiments. T.S. and Y.K. contributed to the experiments using tendon-derived cells. S.I., and  
358 H.H. supervised the project. N.I. and K.O. provided financial support. T.S., B.O., and K.O. prepared  
359 the paper with assistance from the other authors.

360

361 **References**

362

- 363 1. Blomgran P, Hammerman M, Aspenberg P. Systemic corticosteroids improve tendon healing  
364 when given after the early inflammatory phase. *Sci Rep.* 2017;7(1):12468.
- 365 2. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal  
366 and regeneration: Wnt signaling and stem cell control. *Science.* 2014;346(6205):1248012.
- 367 3. Cook JL, Feller JA, Bonar SF, Khan KM. Abnormal tenocyte morphology is more prevalent  
368 than collagen disruption in asymptomatic athletes' patellar tendons. *J Orthop Res.*  
369 2004;22(2):334-338.
- 370 4. Dietrich-Zagonel F, Hammerman M, Tatting L, et al. Stimulation of Tendon Healing With  
371 Delayed Dexamethasone Treatment Is Modified by the Microbiome. *Am J Sports Med.*  
372 2018;46(13):3281-3287.
- 373 5. Docheva D, Muller SA, Majewski M, Evans CH. Biologics for tendon repair. *Adv Drug*  
374 *Deliv Rev.* 2015;84:222-239.
- 375 6. Ganestam A, Kallelose T, Troelsen A, Barfod KW. Increasing incidence of acute Achilles  
376 tendon rupture and a noticeable decline in surgical treatment from 1994 to 2013. A  
377 nationwide registry study of 33,160 patients. *Knee Surg Sports Traumatol Arthrosc.*  
378 2016;24(12):3730-3737.
- 379 7. Gazzaniga AB, James JM, Shobe JB, Oppenheim EB. Prevention of peritoneal adhesions in  
380 the rat. The effects of dexamethasone, methylprednisolone, promethazine, and human  
381 fibrinolysin. *Arch Surg.* 1975;110(4):429-432.
- 382 8. Grissinger M. Preventing serious tissue injury with intravenous promethazine (phenergan).  
383 *P t.* 2009;34(4):175-176.
- 384 9. Hammerman M, Blomgran P, Ramstedt S, Aspenberg P. COX-2 inhibition impairs  
385 mechanical stimulation of early tendon healing in rats by reducing the response to  
386 microdamage. *J Appl Physiol (1985).* 2015;119(5):534-540.
- 387 10. Hogan MV, Bagayoko N, James R, et al. Tissue engineering solutions for tendon repair. *J*  
388 *Am Acad Orthop Surg.* 2011;19(3):134-142.
- 389 11. Ito Y, Toriuchi N, Yoshitaka T, et al. The Mohawk homeobox gene is a critical regulator of  
390 tendon differentiation. *Proc Natl Acad Sci U S A.* 2010;107(23):10538-10542.
- 391 12. Kasai T, Nakatani M, Ishiguro N, et al. Promethazine Hydrochloride Inhibits Ectopic Fat  
392 Cell Formation in Skeletal Muscle. *Am J Pathol.* 2017;187(12):2627-2634.
- 393 13. Kia C, Baldino J, Bell R, et al. Platelet-Rich Plasma: Review of Current Literature on its  
394 Use for Tendon and Ligament Pathology. *Curr Rev Musculoskelet Med.* 2018;11(4):566-  
395 572.
- 396 14. Kishimoto Y, Ohkawara B, Sakai T, et al. Wnt/beta-catenin signaling suppresses expressions  
397 of Scx, Mxk, and Tnmd in tendon-derived cells. *PLoS One.* 2017;12(7):e0182051.
- 398 15. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendon healing in vitro:  
399 effects of TGF-beta on tendon cell collagen production. *J Hand Surg Am.* 2002;27(4):615-  
400 620.
- 401 16. Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, Campbell PG. Insulin-like growth factor I  
402 accelerates functional recovery from Achilles tendon injury in a rat model. *Am J Sports*  
403 *Med.* 1999;27(3):363-369.
- 404 17. Lanske B, Karaplis AC, Lee K, et al. PTH/PTHrP receptor in early development and Indian  
405 hedgehog-regulated bone growth. *Science.* 1996;273(5275):663-666.
- 406 18. Lindsay WK, Walker FG. The effect of an antihistamine (promethazine) on digital flexor  
407 tendon healing in the chicken. *Plast Reconstr Surg Transplant Bull.* 1961;28:634-648.
- 408 19. Lui PP. Stem cell technology for tendon regeneration: current status, challenges, and future  
409 research directions. *Stem Cells Cloning.* 2015;8:163-174.
- 410 20. Majewski M, Heisterbach P, Jaquiere C, et al. Improved tendon healing using bFGF, BMP-  
411 12 and TGFbeta1 in a rat model. *Eur Cell Mater.* 2018;35:318-334.
- 412 21. Majidinia M, Aghazadeh J, Jahanban-Esfahlani R, Yousefi B. The roles of Wnt/beta-catenin  
413 pathway in tissue development and regenerative medicine. *J Cell Physiol.*  
414 2018;233(8):5598-5612.

- 415 22. Miyamoto K, Ohkawara B, Ito M, et al. Fluoxetine ameliorates cartilage degradation in  
416 osteoarthritis by inhibiting Wnt/beta-catenin signaling. *PLoS One*. 2017;12(9):e0184388.  
417 23. Murchison ND, Price BA, Conner DA, et al. Regulation of tendon differentiation by  
418 scleraxis distinguishes force-transmitting tendons from muscle-anchoring tendons.  
419 *Development*. 2007;134(14):2697-2708.  
420 24. Nakamichi R, Kataoka K, Asahara H. Essential role of Mohawk for tenogenic tissue  
421 homeostasis including spinal disc and periodontal ligament. *Mod Rheumatol*.  
422 2018;28(6):933-940.  
423 25. Ng LF, Kaur P, Bunnag N, et al. WNT Signaling in Disease. *Cells*. 2019;8(8).  
424 26. Ozeki N, Muneta T, Koga H, et al. Transplantation of Achilles tendon treated with bone  
425 morphogenetic protein 7 promotes meniscus regeneration in a rat model of massive  
426 meniscal defect. *Arthritis Rheum*. 2013;65(11):2876-2886.  
427 27. Screen HR, Berk DE, Kadler KE, Ramirez F, Young MF. Tendon functional extracellular  
428 matrix. *J Orthop Res*. 2015;33(6):793-799.  
429 28. Sheth U, Wasserstein D, Jenkinson R, et al. The epidemiology and trends in management of  
430 acute Achilles tendon ruptures in Ontario, Canada: a population-based study of 27 607  
431 patients. *Bone Joint J*. 2017;99-b(1):78-86.  
432 29. Wada S, Lebaschi AH, Nakagawa Y, et al. Postoperative Tendon Loading With Treadmill  
433 Running Delays Tendon-to-Bone Healing: Immunohistochemical Evaluation in a Murine  
434 Rotator Cuff Repair Model. *J Orthop Res*. 2019;37(7):1628-1637.  
435 30. Wang Y, Tang H, He G, et al. High Concentration of Aspirin Induces Apoptosis in Rat  
436 Tendon Stem Cells via Inhibition of the Wnt/beta-Catenin Pathway. *Cell Physiol Biochem*.  
437 2018;50(6):2046-2059.  
438